Business
LifeVantage Announces Completion of International In Vitro Study on the MB System™
Recent Study Testing International Formulation Shows Significant Increase in GLP-1 Hormone SALT LAKE CITY, Feb. 04, 2025 (GLOBE NEWSWIRE) -- LifeVantage
About this update from Lifevantage Corporation
[{"type":"text","content":"Recent Study Testing International Formulation Shows Significant Increase in GLP-1 Hormone\nSALT LAKE CITY, Feb. 04, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation® (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced the completion of an international in vitro cell study that investigated the effects of its international formulation for the MindBody GLP-1 System™, known as the MB System™, on activating GLP-1 production.* The international formula was designed to deliver all the benefits of the US formula while meeting regulatory requirements for all other markets in which LifeVantage operates. The study on the international formula, similar to the one completed on the US formula prior to its launch, was conducted on specialized L-cells found in the colon, where the body naturally produces GLP-1, a critical hormone in weight management and glucose regulation. Key genes involved in the production and regulation of GLP-1 and associated neuropeptides were thoroughly examined, including: GCG: Directs the production of Proglucagon, a precursor protein essential for GLP-1 synthesis. GLP1R: Facilitates the creation of receptors that GLP-1 binds to, enabling its biological activity. DPP-4: An enzyme that degrades GLP-1, reducing the amount available in the body. PYY and PPY: Support the production of neuropeptides that work with GLP-1 along the gut-brain axis to regulate hunger signals. The study used ELISA (Enzyme-Linked Immunosorbent Assay) to quantify total GLP-1 production, complemented by fluorescent microscopy to visualize the outcomes. The research focused on determining the synergistic potential of the active blends from the two-product system, which was designed to enhance the body’s GLP-1 production through a dual mechanism: direct activation of L-cells with a proprietary blend of five naturally-derived ingredients and optimization of the gut microbiome environment using resistant starches.* “The completion of this trial and the positive results we’re starting to see with this international formula affirm our success in activating the body’s own production of the GLP-1 hormone,” says Lisa Barnes, VP of R&D and Regulatory at LifeVantage. “We’re excited to bring the MB System™ to our international audience starting in March and ...